Shire Wins European Backing for Vyvanse Attention Deficit Drug

Shire Plc (SHP) won backing to sell its attention deficit drug Vyvanse in eight European countries, paving the way for the company’s top-selling treatment in the U.S. to be marketed in Europe.

The U.K., Denmark, Finland, Germany, Ireland, Norway, Spain and Sweden have recommended approval for Vyvanse as a treatment for children aged six years and over with attention deficit hyperactivity disorder, who don’t respond adequately to Novartis AG (NOVN)’s Ritalin, Dublin-based Shire said in a statement today. The drug will be sold as Tyvense in Ireland and as Elvanse in the other countries.

The eight nations are expected to formally approve the drug within one month to three months, and negotiations with pricing and reimbursement authorities will be required in some countries, Shire, which has management offices in Basingstoke, England, said in the statement. Vyvanse earned Shire $805 million last year, or 19 percent of sales. It may reap $2.2 billion by 2017, according to the average of five analyst estimates compiled by Bloomberg.

“We will now work closely with the pricing and reimbursement authorities in the respective countries to ensure that Elvanse is made available to patients as soon as possible,” Angus Russell, Shire’s chief executive officer, said in the statement.

Shire rose 0.1 percent to 1,925 pence as of 3:01 p.m. in London, giving the company a market value of 10.8 billion pounds ($17.5 billion). The stock has declined 14 percent this year, including reinvested dividends, compared with a 17 percent advance in the Bloomberg Europe Pharmaceutical Index.

To contact the reporter on this story: Simeon Bennett in Geneva at sbennett9@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.